10-Q: Creative Medical Technology Holdings Reports First Quarter 2025 Results, Citing Progress in Clinical Trials and Warrant Exercises

Creative Medical Technology Holdings reports its financial results for the first quarter of 2025, highlighting revenue generation, increased R&D spending, and proceeds from warrant exercises.

Summary

• Creative Medical Technology Holdings, Inc. reported financial results for the quarter ended March 31, 2025.
• The company generated $3,000 in revenue, a notable increase compared to the same period last year.
• The cost of revenues was $1,200, resulting in a gross profit of $1,800.
• Operating expenses increased to $1,662,278, driven by higher research and development and selling, general, and administrative costs.
• Research and development expenses rose to $743,304, primarily due to increased spending on general research and the CELZ-201 ADAPT clinical trial.
• Selling, general, and administrative expenses increased to $888,397, attributed to higher marketing expenses and insurance payments.
• The company reported an operating loss of $1,660,478 and a net loss of $1,638,097, or $0.83 per share.
• The company completed a warrant exercise inducement offer, generating net proceeds of approximately $3.7 million.
• As of March 31, 2025, the company had $7,702,867 in cash and positive working capital of $7,557,624.
• The company is advancing its clinical programs, including the CELZ-201 ADAPT trial for chronic lower back pain and the CELZ-201 CREATE-1 trial for Type 1 Diabetes.

Sentiment

Score: 5

Explanation: The company is making progress in its clinical trials and has secured additional funding through warrant exercises, but it is still operating at a loss and faces significant risks and uncertainties.

Positives

• The company generated revenue of $3,000, marking a step towards commercialization.
• The successful warrant exercise inducement offer brought in $3.7 million, strengthening the company's financial position.
• The CELZ-201 ADAPT clinical trial is progressing, with the DSMB recommending continuation to the next cohort.
• The company secured FDA authorization for an expanded access therapy using CELZ-201 for managing abnormal glucose tolerance and preventing Type I Diabetes in high-risk individuals.
• The company received Orphan Drug Designation (ODD) from the FDA for the treatment of Brittle Type 1 Diabetes using its ImmCelz (CELZ-100) platform.

Negatives

• The company experienced a net loss of $1,638,097 for the quarter, an increase from the $1,041,544 loss in the same period last year.
• Operating expenses significantly increased due to higher research and development and administrative costs.
• The company's accumulated deficit has increased to $66,230,010.
• The company has a limited operating history and has generated minimal revenues from its operations.

Risks

• The company's business and operations are sensitive to general business and economic conditions.
• The company has limited marketing and/or distribution capabilities.
• The company's industry is characterized by rapid changes in technology and customer demands.
• The company may experience technical or other difficulties that could delay or prevent the development, introduction or marketing of new products and services.
• The company may not have the capital resources to further the development of existing and/or new ones.

Future Outlook

The company is focused on advancing its clinical programs, including the CELZ-201 ADAPT trial for chronic lower back pain and the CELZ-201 CREATE-1 trial for Type 1 Diabetes, and is evaluating collaborators, partners, and business opportunities to accelerate development.

Management Comments

• The company believes that the ImmCelz platform has the ability to treat multiple indications.
• The company believes that the development of the iPSC cell line will save the Company two to three years in research and development time along with associated expenses.
• The company believes that the AlloStem Clinical Cell Line (CELZ-200) will be able to be used for many of our programs.
• The company believes that the results of independent studies show that we will be able to substantially reduce production costs, while allowing for the manufacture of the best clinical product for patients with immune disorders, which will enable us to accelerate our clinical applications and encourage potential collaborations with respect to our ImmCelz platform.
• The company believes that the development of human induced pluripotent stem cells (iPSCs)-derived islet cells that produce human insulin has the potential for not only clinical translation of the human Islet Cells, but also the stand-alone human insulin which is produced by these cells.
• The company believes that the use of AI strengthens the Companys research efficiency, precision, and innovation.

Industry Context

The company operates in the competitive biotechnology industry, focusing on novel biological therapeutics in immunotherapy, endocrinology, urology, neurology, and orthopedics, with a focus on stem cell and immune cell-based therapies.

Comparison to Industry Standards

• The company's ImmCelz platform requires 75% fewer donor patient cells compared to industry standards, potentially reducing production costs.
• The purity of the final ImmCelz product was greater than 95% compared to the industry standard of greater than 80%, suggesting a higher quality product.
• The company's ImmCelz platform demonstrated a greater than 200% reduction in functional suppression of effector T cells, which are a critical concern for patients with autoimmune issues, while still possessing a high number of functional T regulatory cells.

Related Party Transactions

• On February 2, 2016, the Company acquired a patent from CMH, a related company, in exchange for 43,112 shares of CMTH common stock valued at $100,000.
• On May 17, 2017, The Company, through its subsidiary StemSpine, LLC, acquired a patent from CMH, a related company, covering the use of various stem cells for the treatment of lower back pain from pursuant to a Patent Purchase Agreement, which was amended in November 2017.
• On December 28, 2020, ImmCelz, Inc. (ImmCelz), a newly formed Nevada corporation and wholly owned subsidiary of the Company, entered into a Patent License Agreement dated December 28, 2020 (the Agreement), with Jadi Cell, LLC. (Jadi), a company controlled by Dr. Amit Patel, a former director of the Company.
• On May 14, 2024, Timothy Warbington, our Chief Executive Officer, purchased one share of our newly designated Series B Preferred Stock for a purchase price of $100.

Stakeholder Impact

• Shareholders: The company's financial performance and clinical trial progress will impact shareholder value.
• Employees: The company's growth and development efforts will affect employment opportunities and job security.
• Patients: The company's clinical trials and potential therapies could provide new treatment options for various diseases.
• Suppliers: The company's research and development activities will drive demand for supplies and services.
• Creditors: The company's financial stability and access to capital will impact its ability to meet its obligations.

Next Steps

• Continue treating the second cohort in the CELZ-201 ADAPT clinical trial.
• Advance clinical programs, including the CELZ-201 ADAPT trial for chronic lower back pain and the CELZ-201 CREATE-1 trial for Type 1 Diabetes.
• Evaluate collaborators, partners, and business opportunities to accelerate development.

Key Dates

Keywords

CELZ-201, ImmCelz, StemSpine, AlloStem, clinical trial, warrants, revenue, research and development, biotechnology, Type 1 Diabetes, lower back pain